Adeno-Associated Viral Vector Manufacturing Market

Global Adeno-Associated Viral Vector Manufacturing Market Size, Trends & Analysis - Forecasts to 2027 By Type (Single-stranded AAV (ssAAV) and Self-complementary AAV (scAAV)), By Application (Hemophilia, Ophthalmology, Lysosomal Storage Disorders, Neurological Disorders, and Others), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa), Company Market Share Analysis, and Competitor Analysis

Category Healthcare
Format
  • ms word
  • ms excel
  • ms ppt
  • pdf
This report was recently updated on November 29 2022 with the latest and most recent market numbers

Adeno-Associated Viral Vector Manufacturing Market Size

The Global Adeno-Associated Viral Vector Manufacturing Market is projected to grow at a CAGR value of 22.9% from 2022 to 2027. The growing investment into the development of vaccines for viral outbreaks has led to a rapid increase in demand for adeno-associated viral vector manufacturing. Demand for efficient manufacturing and packaging of vaccines as a part of the strategy to combat the spread of COVID has also played a crucial role in the growing investment into adeno-associated viral vector manufacturing by pharmaceutical companies.

Government investment and initiatives to ramp up vaccine production and growing investment from the private sector for pharmaceutical manufacturing are expected to further enhance the growth of the adeno-associated viral vector manufacturing market.

The growing number of children being born with genetic disorders and the large number of people suffering from such conditions have also contributed to the growing demand for viral vector manufacturing methods such as adeno-associated viral vector manufacturing. The growing number of people suffering from infectious diseases and the rising rates of infection have all contributed to the growth of the adeno-associated viral vector manufacturing market.

The growing expansion of vaccine production owing to the COVID-19 pandemic has been instrumental in the development of the adeno-associated viral vector manufacturing market in recent years. With over 17 vaccines being used in the fight against COVID, governments have increased efforts to ensure vaccines are being manufactured, stored, and transported in a safe manner. With various vaccines still in developmental stages and over 6 billion doses of vaccines administered by the end of 2021, the adeno-associated viral vector manufacturing market is expected to witness tremendous growth during the forecast period.

Growing investment into research and development of novel vaccines as pharmaceutical companies race to complete clinical trials and attain government approvals to get their vaccine into the market is expected to increase the demand for adeno-associated viral vector manufacturing.

The growing application of adeno-associated viral vector manufacturing in the field of oncology is being increasingly researched. Positive results from the initial phases of clinical trials are expected to further increase the demand for adeno-associated viral vector manufacturing.

The growing number of viral disease outbreaks have seen an increase in investment for the research and development of novel vaccines. The growing number of clinical trials to study viral outbreaks, allergies, and other immunotherapies are expected to increase the demand for adeno-associated viral vector manufacturing. The demand for effective therapeutics for cancer detection, prevention, and cure owing to the growing number of people suffering from cancer is expected to provide lucrative opportunities for growth for the adeno-associated viral vector manufacturing market.

The COVID-19 pandemic has increased the demand for adeno-associated viral vector manufacturing. Growing government initiatives, increased investment in pharmaceutical manufacturing, and the demand for vaccines has been instrumental in the rapid growth of the adeno-associated viral vector manufacturing market during COVID-19. The market is expected to continue to grow post-pandemic, as adeno-associated viral vector manufacturing is being increasingly utilized in other fields.

The growth of the adeno-associated viral vector manufacturing market is restrained by the use of the high cost of such manufacturing procedures, the need for skilled professionals, and the growing number of challenges to viral vector manufacturing capabilities compared to other manufacturing methods.

The adeno-associated viral vector manufacturing market is largely driven by the growing demand for vaccine manufacturing, increasing investment into viral vaccine R&D, growing adoption of adeno-associated viral vector manufacturing in the oncology field, and the growing prevalence of genetic disorders, infectious diseases.

global adeno associated viral vector manufacturing market

Adeno-Associated Viral Vector Manufacturing Market: By Method

Based on the method, the adeno-associated viral vector manufacturing market is segmented into Single-stranded AAV (ssAAV) and Self-complementary AAV (scAAV). The Single-stranded AAV (ssAAV) segment is expected to hold the largest piece of the market during the forecast period. The growing adoption of single-stranded AAV (ssAAV) in infectious diseases vaccine development has been the major driver of the segment.

Adeno-Associated Viral Vector Manufacturing Market: By Application

Based on the various avenues of application of adeno-associated viral vector manufacturing, the market is segmented into hemophilia, ophthalmology, lysosomal storage disorders, neurological disorders, and others. The ophthalmology segment held the lion’s share of the market. The increased investment in the development of gene therapy for genetic eye disorders has led to the development of the ophthalmology segment. The hemophilia segment is expected to become the fastest-growing segment in the market.

asia pacific adeno associated viral vector manufacturing market

Adeno-Associated Viral Vector Manufacturing Market: By Region

Based on region, the market can be segmented into various regions such as North America, Europe, Central and South America, Middle East and North Africa, and Asia Pacific regions.

The North American region is expected to be the dominant force in the market during the forecast period. The large number of pharmaceutical companies operating out of this region, heavy investment into R&D of pharmaceutical products, vaccine development, string healthcare infrastructure, and heavy spending on healthcare by governments in the region have contributed to the growth of the North American market in the adeno-associated viral vector manufacturing market.

The APAC region is expected to become the fastest-growing segment during the forecast period. The growing pharmaceuticals manufacturing in the region and growing investment in gene therapy in the region is expected to become the fastest-growing region.

Adeno-Associated Viral Vector Manufacturing Market Share and Competitor Analysis

Biomarin Pharmaceutical, Sarepta Therapeutics, Roche (Spark Therapeutics), Sangamo, Pfizer, NightstaRx, Freeline Therapeutics, Horama S.A,MeiraGTx, RegenxBio, Asklepios Biopharmaceutical, and Audentes Therapeutics, among others, are the key players in the adeno-associated viral vector manufacturing market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1   Methodology

1.1    Market Scope & Definitions

1.2    Estimates & Forecast Calculation

1.3    Historical Data Overview and Validation

1.4    Data Sources

1.4.1    Secondary

1.4.2    Primary

Chapter 2   Report Outlook

2.1    Adeno-Associated Viral Vector Manufacturing Industry Overview, 2020-2026

2.1.1    Industry Overview

2.1.2    Type Overview

2.1.3    Application Overview

2.1.4    Regional Overview

Chapter 3   Adeno-Associated Viral Vector Manufacturing Market Trends

3.1    Market Segmentation

3.2    Industry Background, 2020-2026

3.3    Market Key Trends

3.3.1    Positive Trends

3.3.1.1    Increasing investment in pharmaceuticals R&D

3.3.2    Industry Challenges

3.3.2.1    Rise in cost and dearth of qualified professionals

3.4    Prospective Growth Scenario

3.4.1    Type Growth Scenario

3.4.2    Application Growth Scenario

3.5    COVID-19 Influence over Industry Growth

3.6    Porter’s Analysis

3.7    PESTEL Analysis

3.8    Value Chain & Supply Chain Analysis

3.9    Regulatory Framework

3.9.1    North America

3.9.2    Europe

3.9.3    APAC

3.9.4    LATAM

3.9.5    MEA

3.10    End-User Overview

3.11    Market Share Analysis, 2020

3.11.1    Company Positioning Overview, 2020

Chapter 4   Adeno-Associated Viral Vector Manufacturing Market, By Type

4.1    Type Outlook

4.2    Single-stranded AAV (ssAAV)

4.2.1    Market Size, By Region, 2020-2026 (USD Million)

4.3    Self-complementary AAV (scAAV)

4.3.1    Market Size, By Region, 2020-2026 (USD Million)

Chapter 5   Adeno-Associated Viral Vector Manufacturing Market, By Application

5.1    Application Outlook

5.2    Hemophilia

5.2.1    Market Size, By Region, 2020-2026 (USD Million)

5.3    Ophthalmology

5.3.1    Market Size, By Region, 2020-2026 (USD Million)

5.4    Lysosomal Storage Disorders

5.4.1    Market Size, By Region, 2020-2026 (USD Million)

5.5    Neurological Disorders

5.5.1    Market Size, By Region, 2020-2026 (USD Million)

5.6    Others

5.6.1    Market Size, By Region, 2020-2026 (USD Million)

Chapter 6   Adeno-Associated Viral Vector Manufacturing Market, By Region

6.1    Regional outlook

6.2    North America

6.2.1    Market Size, By Country 2020-2026 (USD Million)

6.2.2    Market Size, By Type, 2020-2026 (USD Million)

6.2.3    Market Size, By Application, 2020-2026 (USD Million)

6.2.4    U.S.

6.2.4.1    Market Size, By Type, 2020-2026 (USD Million)

6.2.4.2    Market Size, By Application, 2020-2026 (USD Million)

6.2.5    Canada

6.2.5.1    Market Size, By Type, 2020-2026 (USD Million)

6.2.5.2    Market Size, By Application, 2020-2026 (USD Million)

6.3    Europe

6.3.1    Market Size, By Country 2020-2026 (USD Million)

6.3.2    Market Size, By Type, 2020-2026 (USD Million)

6.3.3    Market Size, By Application, 2020-2026 (USD Million)

6.3.4    Germany

6.3.4.1    Market Size, By Type, 2020-2026 (USD Million)

6.3.4.2    Market Size, By Application, 2020-2026 (USD Million)

6.3.5    UK

6.3.5.1    Market Size, By Type, 2020-2026 (USD Million)

6.3.5.2    Market Size, By Application, 2020-2026 (USD Million)

6.3.6    France

6.3.6.1    Market Size, By Type, 2020-2026 (USD Million)

6.3.6.2    Market Size, By Application, 2020-2026 (USD Million)

6.3.7    Italy

6.3.7.1    Market Size, By Type, 2020-2026 (USD Million)

6.3.7.2    Market Size, By Application, 2020-2026 (USD Million)

6.3.8    Spain

6.3.8.1    Market Size, By Type, 2020-2026 (USD Million)

6.3.8.2    Market Size, By Application, 2020-2026 (USD Million)

6.3.9    Russia

6.3.9.1    Market Size, By Type, 2020-2026 (USD Million)

6.3.9.2    Market Size, By Application, 2020-2026 (USD Million)

6.4    Asia Pacific

6.4.1    Market Size, By Country 2020-2026 (USD Million)

6.4.2    Market Size, By Type, 2020-2026 (USD Million)

6.4.3    Market Size, By Application, 2020-2026 (USD Million)

6.4.4    China

6.4.4.1    Market Size, By Type, 2020-2026 (USD Million)

6.4.4.2    Market Size, By Application, 2020-2026 (USD Million)

6.4.5    India

6.4.5.1    Market Size, By Type, 2020-2026 (USD Million)

6.4.5.2    Market Size, By Application, 2020-2026 (USD Million)

6.4.6    Japan

6.4.6.1    Market Size, By Type, 2020-2026 (USD Million)

6.4.6.2    Market Size, By Application, 2020-2026 (USD Million)

6.4.7    Australia

6.4.7.1    Market Size, By Type, 2020-2026 (USD Million)

6.4.7.2    Market size, By Application, 2020-2026 (USD Million)

6.4.8    South Korea

6.4.8.1    Market Size, By Type, 2020-2026 (USD Million)

6.4.8.2    Market Size, By Application, 2020-2026 (USD Million)

6.5    Latin America

6.5.1    Market Size, By Country 2020-2026 (USD Million)

6.5.2    Market Size, By Type, 2020-2026 (USD Million)

6.5.3    Market Size, By Application, 2020-2026 (USD Million)

6.5.4    Brazil

6.5.4.1    Market Size, By Type, 2020-2026 (USD Million)

6.5.4.2    Market Size, By Application, 2020-2026 (USD Million)

6.5.5    Mexico

6.5.5.1    Market Size, By Type, 2020-2026 (USD Million)

6.5.5.2    Market Size, By Application, 2020-2026 (USD Million)

6.5.6    Argentina

6.5.6.1    Market Size, By Type, 2020-2026 (USD Million)

6.5.6.2    Market Size, By Application, 2020-2026 (USD Million)

6.6    MEA

6.6.1    Market Size, By Country 2020-2026 (USD Million)

6.6.2    Market Size, By Type, 2020-2026 (USD Million)

6.6.3    Market Size, By Application, 2020-2026 (USD Million)

6.6.4    Saudi Arabia

6.6.4.1    Market Size, By Type, 2020-2026 (USD Million)

6.6.4.2    Market Size, By Application, 2020-2026 (USD Million)

6.6.5    UAE

6.6.5.1    Market Size, By Type, 2020-2026 (USD Million)

6.6.5.2    Market Size, By Application, 2020-2026 (USD Million)

6.6.6    South Africa

6.6.6.1    Market Size, By Type, 2020-2026 (USD Million)

6.6.6.2    Market Size, By Application, 2020-2026 (USD Million)

Chapter 7   Company Landscape

7.1    Competitive Analysis, 2020

7.2    Biomarin Pharmaceutical

7.2.1    Company Overview

7.2.2    Financial Analysis

7.2.3    Strategic Positioning

7.2.4    Info Graphic Analysis

7.3     Sarepta Therapeutics

7.3.1    Company Overview

7.3.2    Financial Analysis

7.3.3    Strategic Positioning

7.3.4    Info Graphic Analysis

7.4    Roche (Spark Therapeutics)

7.4.1    Company Overview

7.4.2    Financial Analysis

7.4.3    Strategic Positioning

7.4.4    Info Graphic Analysis

7.5    Sangamo

7.5.1    Company Overview

7.5.2    Financial Analysis

7.5.3    Strategic Positioning

7.5.4    Info Graphic Analysis

7.6    Pfizer

7.6.1    Company Overview

7.6.2    Financial Analysis

7.6.3    Strategic Positioning

7.6.4    Info Graphic Analysis

7.7    NightstaRx

7.7.1    Company Overview

7.7.2    Financial Analysis

7.7.3    Strategic Positioning

7.7.4    Info Graphic Analysis

7.8    Freeline Therapeutics

7.8.1    Company Overview

7.8.2    Financial Analysis

7.8.3    Strategic Positioning

7.8.4    Info Graphic Analysis

7.9    Horama S.A

7.9.1    Company Overview

7.9.2    Financial Analysis

7.9.3    Strategic Positioning

7.9.4    Info Graphic Analysis

7.10    Other Companies

7.10.1    Company Overview

7.10.2    Financial Analysis

7.10.3    Strategic Positioning

7.10.4    Info Graphic Analysis

The Global Adeno-Associated Viral Vector Manufacturing Market has been studied from the year 2019 till 2027. However, the CAGR provided in the report is from the year 2022 to 2027. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Adeno-Associated Viral Vector Manufacturing Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.
This website is secure and your personal details are safe. Privacy

Frequently Asked Questions

The global adeno-associated viral vector manufacturing market size is projected to grow at a CAGR value of 22.9% from 2022 and 2027.
Key and innovative vendors in the adeno-associated viral vector manufacturing market include Biomarin Pharmaceutical, Sarepta Therapeutics, Roche (Spark Therapeutics), Sangamo, Pfizer, NightstaRx, Freeline Therapeutics, Horama S.A, MeiraGTx, RegenxBio, Asklepios Biopharmaceutical, and Audentes Therapeutics, among others.
The North American region is estimated to hold the largest share of the adeno-associated viral vector manufacturing market.
The COVID-19 pandemic has increased the demand for adeno-associated viral vector manufacturing. Growing government initiatives, increased investment in pharmaceutical manufacturing, and the demand for vaccines has been instrumental in the rapid growth of the adeno-associated viral vector manufacturing market during COVID-19. The market is expected to continue to grow post-pandemic, as adeno-associated viral vector manufacturing is being increasingly utilized in other fields.
The adeno-associated viral vector manufacturing market is largely driven by the growing demand for vaccine manufacturing, increasing investment into viral vaccine R&D, growing adoption of adeno-associated viral vector manufacturing in the oncology field, and the growing prevalence of genetic disorders, infectious diseases.

Tailor made solutions just for you

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

OUR CLIENTS

  • Client of Global Market Estimates - Fedex
  • Client of Global Market Estimates - Samsung
  • Client of Global Market Estimates - Siemens
  • Client of Global Market Estimates - Lonza
  • Client of Global Market Estimates - DuPont
  • Client of Global Market Estimates - Medtronic
  • Client of Global Market Estimates - Toray
  • Client of Global Market Estimates - Signify
  • Client of Global Market Estimates - Teledyne
  • Client of Global Market Estimates - Trelleborg
  • Client of Global Market Estimates - Kikkoman Biochemifa
  • Client of Global Market Estimates - Leoni
  • Client of Global Market Estimates - Molnlycke
  • Client of Global Market Estimates - Spirent
  • Client of Global Market Estimates - Tokyo Electron Limited
  • Client of Global Market Estimates - Aranca
  • Client of Global Market Estimates - Asahi Kasei
  • Client of Global Market Estimates - Chimai
  • Client of Global Market Estimates - Grapsud
  • Client of Global Market Estimates - Horiba
  • Client of Global Market Estimates - Indorama
  • Client of Global Market Estimates - L&T
  • Client of Global Market Estimates - Integralife
  • Client of Global Market Estimates - Synamedia
  • Client of Global Market Estimates - Sorrento Therapeutics
  • Client of Global Market Estimates - Solenis
  • Client of Global Market Estimates - Sartorius